Tazemetostat, which inhibits both Y641N-mutant and wild-type forms of EZH2, has been shown to induce cell cycle arrest and apoptosis in preclinical models of follicular lymphoma [116,117]. The gene discussed is EZH2; the disease is follicular lymphoma.